Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study

Table 3

Safety profile of NDLS based chemotherapy in sarcoma (n = 11).

Adverse event	All grades, n (%)	Grade I, n (%)	Grade II, n (%)
Hematological AEs
Neutropenia	2 (18.2)		2 (18.2)
Thrombocytopenia	1 (9.1)	1 (9.1)
Anemia	1 (9.1)	1 (9.1)
Lymphopenia	1 (9.1)	1 (9.1)
Nonhematological AEs
Nausea	4 (36.4)	4 (36.4)
Vomiting	4 (36.4)	4 (36.4)
Diarrhea	3 (27.3)	3 (27.3)
Mucositis	2 (18.2)		2 (18.2)
Mouth ulcer	2 (18.2)	2 (18.2)
Weakness	1 (9.1)
Alopecia	1 (9.1)	1 (9.1)

Note. AEs in different grades may occur in ≥1 patient; hence, the number of cumulative number of patients in different grades may exceed the total number of patients with individual AEs.